Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer [Yahoo! Finance]
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Weiner, Ph.D. — Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research — and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma. Their findings were published in the paper, “Novel tri-specific T-cell engager targeting IL-13Ra2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells,” in the Journal for ImmunoTherapy of Cancer. “This study utilizes a novel design to build a glioblastoma-targeting ‘trispecific' antibody deployed against a laboratory model of glioblastoma, which has the potential to be made entirely in patients as a glioblastoma therapy in the future,” said corresponding author, Dr. David Weiner. “We're hopeful that this will have future applications for preventing tumor escape mechanisms that bloc
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035, Featuring Profiles of Halozyme, HNS, INOVIO Pharmaceuticals and Medical International Technology and PharmaJet [Yahoo! Finance]Yahoo! Finance
- INOVIO Announces Pricing of $30 Million Public OfferingPR Newswire
- INOVIO Announces Proposed Public OfferingPR Newswire
- New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial [Yahoo! Finance]Yahoo! Finance
- New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 TrialPR Newswire
INO
Earnings
- 11/14/24 - Beat
INO
Sec Filings
- 12/23/24 - Form SCHEDULE
- 12/18/24 - Form 4
- 12/16/24 - Form 8-K
- INO's page on the SEC website